Besides, antisense nucleotide inhibitors against hepatic Scd1 prevent HFD induced hepatic steatosis, and Scd1 inhibitors are claimed to be new treatments for NASH [33]. This evidence concerns the gene SCD and metabolic dysfunction-associated steatohepatitis.